For millions worldwide, the diagnosis of actinic keratosis (AK) marks the beginning of a challenging journey to prevent skin cancer.…
Read More
Rubedo Life Sciences’ RLS-1496 Shows Promise in Treating Precancerous Skin Lesions with Minimal Irritation
For millions worldwide grappling with actinic keratoses (AK), the rough, scaly patches of sun-damaged skin that are precursors to squamous…
Read More
Rubedo turns a senescence-targeting drug on precancerous skin, and sees an efficacy signal without the intense redness
For millions worldwide, the diagnosis of actinic keratoses (AK) initiates a challenging journey to prevent the progression to skin cancer.…
Read More
Rubedo turns a senescence-targeting drug on precancerous skin, and sees an efficacy signal without the intense redness
Rubedo Life Sciences, an AI-driven biotech startup focused on longevity, has announced positive preliminary results from its Phase 1b/2a study…
Read More
Rubedo turns a senescence-targeting drug on precancerous skin, and sees an efficacy signal without the intense redness
For millions globally afflicted by actinic keratoses (AKs), the rough, scaly patches of sun-damaged skin that serve as precursors to…
Read More
Rubedo Life Sciences Pivots from Cosmetic Enhancement to Biological Rejuvenation with Senescent Cell Clearance for Age-Related Skin Conditions
Dr. Frederick Beddingfield III, a seasoned pharmaceutical executive known for his instrumental role in scaling Botox into a multi-billion-dollar franchise…
Read More
Rubedo Life Sciences Charts Ambitious Course to Reverse Skin Aging and Disease Through Targeted Senescent Cell Clearance
In a significant pivot from the traditional aesthetics market, Rubedo Life Sciences, under the leadership of CEO Dr. Frederick Beddingfield…
Read More
Rubedo Life Sciences Pioneers Senolytic Approach to Reverse Skin Aging and Treat Inflammatory Dermatoses
In a significant shift within the pharmaceutical and longevity sectors, Rubedo Life Sciences, under the leadership of CEO Dr. Frederick…
Read MoreYOU MAY HAVE MISSED
